

Application no.	Drug	Applicant
NDA 12-966	Masterone (dromostanolone propionate)	Hoffman-La Roche, Inc.
NDA 13-071	Libritabs (chlordiazepoxide) Tablets, 5, 10, 25 milligrams (mg).	Do.
NDA 13-664	GANTANOL (sulfamethoxazole) Suspension	Do.
NDA 16-109	Sinubid (acetaminophen, phenylpropanolamine HCl, and phenyltoloxamine citrate) Extended Release Tablets.	Parke-Davis, 2800 Plymouth Rd., Ann Arbor, MI 48105.
NDA 16-943	Halotex (haloprogyn) 1% Solution	Westwood-Squibb Pharmaceuticals, Inc., 100 Forest Ave., Buffalo, NY 14213-1091.
NDA 17-914	OTIC-TRIDESILON (desonide-acetic acid) Solution 0.05%	Bayer Corp., 400 Morgan Ln., West Haven, CT 06516-4175.
NDA 18-366	Chymex (bentiromide) Solution	Savage Laboratories, Division of Altana, Inc., 60 Baylis Rd., Melville, NY 11747.
NDA 18-470	Cibacalcin (calcitonin-human, for injection)	Ciba-Geigy Corp., Summit, NJ 07901.
AADA 62-078	Ampicillin Trihydrate (bulk)	Sandoz Pharmaceuticals, 59 Route 10, East Hanover, NJ 07936-1080.
ANDA 70-120	Propranolol Hydrochloride Tablets, 10 mg	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
ANDA 70-121	Propranolol Hydrochloride Tablets, 20 mg	Do.
ANDA 70-122	Propranolol Hydrochloride Tablets, 40 mg	Do.
ANDA 70-123	Propranolol Hydrochloride Tablets, 60 mg	Do.
ANDA 70-124	Propranolol Hydrochloride Tablets, 80 mg	Do.
ANDA 85-288	Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/30 mg.	KV Pharmaceutical Co., 2503 South Hanley Rd., St. Louis, MO 63144-2555.
ANDA 85-484	Chlorpromazine Hydrochloride Tablets, USP, 50 mg	Do.
ANDA 85-748	Chlorpromazine Hydrochloride Tablets, USP, 200 mg	Do.
ANDA 85-750	Chlorpromazine Hydrochloride Tablets, USP, 10 mg	Do.
ANDA 85-751	Chlorpromazine Hydrochloride Tablets, USP, 25 mg	Do.
ANDA 85-752	Chlorpromazine Hydrochloride Tablets, USP, 100 mg	Do.
ANDA 87-819	Hydroxyzine Hydrochloride Tablets, USP, 10 mg	Do.
ANDA 87-820	Hydroxyzine Hydrochloride Tablets, USP, 25 mg	Do.
ANDA 87-821	Hydroxyzine Hydrochloride Tablets, USP, 50 mg	Do.
ANDA 87-822	Hydroxyzine Hydrochloride Tablets, USP, 100 mg	Do.
ANDA 88-344	Triprolidine Hydrochloride Pseudoephedrine Hydrochloride Syrup, 1.25 mg/30 mg per 5 milliliters (mL).	H. R. Cenci Laboratories, Inc., P.O. Box 12524, Fresno, CA 93778-2524.
ANDA 88-814	Promethazine with Codeine Syrup (Promethazine Hydrochloride and Codeine Phosphate Oral Solution, 6.25 mg/10 mg/5 mL).	Do.
ANDA 88-815	Promethazine VC Plain Syrup (Promethazine Hydrochloride and Phenylephrine Hydrochloride Oral Solution, 6.25 mg/5 mg/5 mL).	Do.
ANDA 88-816	Promethazine Hydrochloride, Phenylephrine Hydrochloride, Codeine Phosphate Syrup, 6.25 mg/5 mg/10 mg per 5 mL.	Do.
ANDA 89-018	Triprolidine Hydrochloride Pseudoephedrine Hydrochloride and Codeine Phosphate Cough Syrup, 1.25 mg/30 mg/10 mg per 5 mL.	Do.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective February 10, 1997.

Dated: December 30, 1996.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 97-524 Filed 1-8-97; 8:45 am]

BILLING CODE 4160-01-F

Health Care Financing Administration

Agency Information Collection Activities: Proposed Collection: Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposals for the collection of information. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information

collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Request:* Revision of a currently approved collection; *Title of Information Collection:* Statistical Report on Medical Care: Eligibles, Recipients, Payments and Services; *Form No.:* HCFA-2082; *Use:* The data reported in the HCFA-2082 are the basis of actuarial forecasts for Medicaid service utilization and costs; of analysis and cost savings estimates required for legislative initiatives relating to

Medicaid and for responding to requests for information from HCFA components, the Department, Congress and other customers.; Frequency: Annually; *Affected Public*: State, local, or tribal government; *Number of Respondents*: 54; *Total Annual Responses*: 54; *Total Annual Hours*: 17,214.

To request copies of the proposed paperwork collection referenced above, E-mail your request, including your address, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections should be sent within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Analysis and Planning Staff, Attention: Linda Mansfield, Room C2-26-17, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: December 31, 1996.

Edwin J. Glatzel,

Director, Management Analysis and Planning Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 97-455 Filed 1-8-97; 8:45 am]

BILLING CODE 4120-03-P

Health Resources and Services Administration

Council on Graduate Medical Education Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), announcement is made of the following National Advisory body scheduled to meet during the month of February 1997:

Name: Council on Graduate Medical Education

Date and Time: February 5, 1997, 1:00 p.m.—5:00 p.m., February 6, 1997, 8:30 a.m.—4:00 p.m.

Place: Omni Shoreham Hotel, 2500 Calvert Street, N.W., Washington, D.C. 20008, Palladian Room.

This meeting is open to the Public.

Agenda: The agenda will include two panel discussions, one is a summary of the current policy environment, the other academic medicine, managed care and GME. Discussions on the suggested future directions for COGME. Reports and recommendations in the following areas: International Medical Graduates and Options Paper—Reducing First-Year Resident Numbers.

Anyone requiring information regarding the subject should contact F. Lawrence Clare, M.D., M.P.H., Deputy Executive Secretary, telephone (301) 443-6326, Council on

Graduate Medical Education, Division of Medicine, Bureau of Health Professions, Room 9A-27, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

Agenda items are subject to change as priorities dictate.

Dated: January 3, 1997.

J. Henry Montes,

Director, Office of Policy and Information Coordination.

[FR Doc. 97-522 Filed 1-8-97; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

National Center for Research Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Center for Research Resources Special Emphasis Panel (SEP) meeting:

Name of SEP: Biomedical Research Technology (Telephone Conference Call).

Date: January 30, 1997.

Time: 2:00 p.m.

Place: National Institutes of Health, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892-7965.

Contact Person: Dr. Sharon Moss, Scientific Review Administrator, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892-7965, (301) 435-0822.

Purpose/Agenda: To evaluate and review contract proposals.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.371, Biomedical Research Technology, National Institutes of Health, HHS)

Dated: January 3, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-447 Filed 1-8-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Preparation of a Joint Environmental Impact Statement /Environmental Impact Report for Federal and State Actions Associated With Furthering the Purposes of the September 28, 1996, Agreement Between the United States, State of California, and MAXXAM, Inc. and its Subsidiary, Pacific Lumber Company

AGENCY: Fish and Wildlife Service, Interior.

Cooperating Agencies: National Marine Fisheries Service, National Oceanic and Atmospheric Administration, Commerce, Environmental Protection Agency, Forest Service, Agriculture, Bureau of Land Management, Interior, California State Resources Agency, California State Department of Forestry and Fire Protection, California State Department of Fish and Game.

ACTION: Notice of additional public scoping meeting and extension of scoping comment period.

SUMMARY: As specified in the official Notice of Intent (FR, Vol. 61, No. 250, p. 68285), five public scoping meetings were scheduled and all scoping comments to the notice were requested to be received by February 10, 1997. This present Notice announces that a sixth public scoping meeting has been scheduled and the above agencies request all scoping comments to this notice be received by February 18, 1997. The sixth public scoping meeting has been scheduled for Tuesday, February 11, 1997, Radisson Plaza Hotel, 1400 Parkview Avenue, Manhattan Beach, California, from 1 p.m. to no later than 4 p.m., and from 6 p.m. to no later than 9 p.m.

ADDRESSES: Comments regarding the scope of the EIS should be addressed to Mr. Bruce Halstead, U.S. Fish and Wildlife Service, 1125 16th Street, Room 209, Arcata, CA 95521-5582. Comments should be received on or before February 18, 1997, at the above address. Written comments may also be sent by facsimile to (707) 822-8136. Comments received will be available for public inspection by appointment during normal business hours (8:00 a.m. to 5:00 p.m., Monday through Friday) at the above office; please call for an appointment.

FOR FURTHER INFORMATION CONTACT: Dennis Mackey, U.S. Fish and Wildlife Service, 911 NE 11th Avenue, Portland,